Business Wire

Elevate Prize Foundation Launches Application for $5M Elevate Prize

10.3.2021 17:00:00 EET | Business Wire | Press release

Share

The Elevate Prize Foundation is pleased to announce the launch of its second year of the Elevate Prize, which will commit $5 million in funding and services to 10 prize winners. The Foundation is searching for social impact leaders globally who are tackling the most pressing challenges of our time, with the most innovative and effective solutions.

Founders and CEOs of nonprofits and public charities worldwide are welcome to apply to win one of 10 annual Elevate Prizes. New this year is a simplified, two-phase application, making it significantly easier for nonprofit leaders to apply for the Prize. Phase 1, now open to all applicants, includes a shortened written application, while Phase 2 will include a more robust set of questions, released only to select applicants this summer.

The Elevate Prize Foundation, founded in 2019 by entrepreneur and philanthropist Joseph Deitch, is dedicated to giving unsung social entrepreneurs the necessary resources to scale their impact, and to ultimately help inspire and awaken the hero in all of us. The Foundation awarded its inaugural class of 10 winners in October 2020.

Each winner of this year’s Elevate Prize will receive:

  • MONEY. A minimum of $300,000 (USD) shared between winners and their nonprofit organizations, so they can collectively drive change.
  • AMPLIFICATION. Our strategic marketing and media expertise can take winners to the next level. Be a social impact influencer. Find fans. Build a platform. Think bigger. Do great things. Change the world.
  • MENTORSHIP. Our network of partners, executives and decision-makers offer the kind of professional development and business guidance money can’t buy.
  • CONNECTIONS. Each cohort is a radically diverse group of people leading innovative organizations. As a member of this cohort, winners will have the opportunity to learn from each other, create shared experiences, and build lasting relationships.
  • SUPPORT. We take the time to thoroughly understand winners’ needs as an individual and organization, and then create a tailored program that will help each winner reach their goals and beyond.

“The Elevate Prize remains committed to finding a radically diverse group of innovative problem solvers, and investing unconventional and personalized resources that bring greater visibility to them as leaders and the vital work they do. We make good famous,” said Carolina García Jayaram, executive director, Elevate Prize Foundation.

The Foundation is proud to partner with MIT Solve on this year’s Elevate Prize. As an extension of its partnership, the Foundation will commit one of its 10 Prizes to MIT Solve’s first US Challenge on Antiracist Technology. The Elevate Prize for Antiracist Technology is open to nonprofit leaders who are helping to create an antiracist and equitable future in the U.S. This exemplar leader will take part in both the MIT Solver program and the Elevate Prize program and receive ongoing support from both organizations.

The application process for the Prize begins today at www.elevateprize.org/apply and applicants can submit up until the May 5 deadline. Following this deadline, select applicants will be invited to complete Phase 2 of the application. Winners will be announced in October 2021.

About the Elevate Prize Foundation

Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, the Elevate Prize Foundation aims to elevate humanity on a global scale by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize – a search for innovators and activists that culminates with the selection of 10 leaders to receive funding and guidance to amplify their work. These changemakers are working to solve the world’s problems within healthcare, the environment, poverty, inequality, the arts, and more. Elevate Prize winners embark on a two-year program fueled by access to top scholars and industry leaders who guide and support them in scaling their impact. Together, Prize winners, advisors, partners, and collaborators across industries combine their impressive reach to create a single, powerful philanthropic amplification platform to awaken the hero in all of us. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook, Instagram, LinkedIn, and Twitter.

About MIT Solve

Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CashmanCo
Lily Freedberg
lily@cashmanco.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release

ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release

BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin

IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye